Elizabeth Hougen Sells 49,800 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Elizabeth Hougen sold 49,800 shares of the business’s stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $65.26, for a total transaction of $3,249,948.00. Following the completion of the sale, the executive vice president directly owned 110,500 shares of the company’s stock, valued at approximately $7,211,230. This trade represents a 31.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ionis Pharmaceuticals Stock Up 4.0%

IONS stock opened at $68.40 on Friday. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -37.17 and a beta of 0.32. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $68.41. The company has a fifty day moving average price of $51.71 and a 200 day moving average price of $40.33. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.51. The company had revenue of $452.00 million for the quarter, compared to analysts’ expectations of $270.90 million. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. Ionis Pharmaceuticals’s revenue was up 100.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.45) EPS. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Exome Asset Management LLC boosted its position in Ionis Pharmaceuticals by 121.0% during the 1st quarter. Exome Asset Management LLC now owns 135,616 shares of the company’s stock worth $4,092,000 after acquiring an additional 74,249 shares during the period. GAMMA Investing LLC lifted its stake in Ionis Pharmaceuticals by 3,786.5% during the first quarter. GAMMA Investing LLC now owns 28,993 shares of the company’s stock valued at $961,000 after purchasing an additional 28,247 shares during the last quarter. Raymond James Financial Inc. boosted its stake in shares of Ionis Pharmaceuticals by 40.8% during the 1st quarter. Raymond James Financial Inc. now owns 148,690 shares of the company’s stock worth $4,486,000 after acquiring an additional 43,071 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of Ionis Pharmaceuticals by 4.8% in the 1st quarter. Fifth Third Bancorp now owns 9,989 shares of the company’s stock valued at $301,000 after purchasing an additional 458 shares during the period. Finally, Edmond DE Rothschild Holding S.A. purchased a new position in shares of Ionis Pharmaceuticals in the first quarter worth approximately $3,747,000. Institutional investors own 93.86% of the company’s stock.

Wall Street Analyst Weigh In

IONS has been the topic of a number of research reports. Needham & Company LLC increased their price objective on shares of Ionis Pharmaceuticals from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Ionis Pharmaceuticals from $48.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, August 25th. Morgan Stanley upped their target price on Ionis Pharmaceuticals from $71.00 to $86.00 and gave the company an “overweight” rating in a research note on Tuesday, September 23rd. The Goldman Sachs Group raised shares of Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and increased their price target for the stock from $45.00 to $65.00 in a research note on Friday, September 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $73.88.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.